Vistagen Therapeutics Gains Momentum; Blend Labs Beats Estimates
- August 10th, 2023
- 420 views
Shares of Vistagen Therapeutics, Inc. (Nasdaq: VTGN) surged over 20% in after-hours trading as Commodore Capital LP disclosed in a regulatory filing (Form 4) with the SEC that it has recently acquired 775,756 shares of Vistagen through multiple transactions, at an average price of $23.153 per share.
The late clinical-stage biopharmaceutical company will be reporting its first-quarter fiscal-year 2024 financial results after the market closes on Thursday, August 10.
$VTGN was trading at $8.65 in after-hours, reflecting a significant increase of $1.61 or 22.96%.
In other news, Blend Labs, Inc. (NYSE: BLND) reported better-than-expected second-quarter 2023 financial results. The company's loss per share came in at $(0.09), outperforming the consensus estimate loss of $(0.13). In addition, Blend Labs achieved quarterly sales of $42.81 million, surpassing analysts' projected revenue of $40.11 million for the period.
In after-hours, $BLND was trading at $1.46, up $0.24 (+19.67%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login